ABSTRACT A series of polyphenolic-sulfonated compounds were observed to have potent anti-inflammatory activity and were protective against induced endotoxic shock in mice at 8 and 16 mg/kg, I.P. These agents proved to be potent elastase inhibitors in human leukocytes and J774-AI and IC-21 mouse macrophages as well as prostaglandin cyclo-oxygenase inhibitors in J774-AI macrophages. The compounds from 5 to 50 tM inhibited TNFot release from IC-21 macrophages and IL-1 release from mouse P388tl macrophages induced by LPS. The binding of these cytokines to high affinity receptors on target cells, e.g. L929 fibroblasts and IL-2 in HUT78 T lymphoma cells, were also suppressed by the agents. These compounds blocked the adhesion of leukocytes and macrophages to the plasma membranes of L929 fibroblasts.
INTRODUCTION
Cyclic imides [1] [2] [3] , -, 13-and y-alkylaminopropiophenones [4] , amine-carboxyboranes and their metal complexes [5, 6] , thiosemicarbazones and their metal complexes [7] , and triazolidinedione derivatives [8] have previously been shown to be potent anti-inflammatory and analgesic agents in rodents. These low molecular weight agents like other non-steroidal anti-inflammatory agents were able to block lysosomal hydrolytic and proteolytic enzyme activities as well as the synthesis of prostaglandins and leukotrienes, chemical mediators of inflammation. In addition they were able to protect against free radicals generated during inflammation. These small molecules blocked the release of cytokines synthesized by macrophages, i.e. TNF and IL-1 and I1-6. The uniqueness of these agents is that they also competitively displace cytokines from binding to their high affinity receptors on L929 cells. Few reports in the literature indicate interaction at these receptor sites other than by peptides or antibodies. Suramin, a polysulfate naphthylurea, has been shown to be an IL-6 high affinity receptor antagonist [6] . Blocking these receptors is desirable because the entire inflammation cascade of events is triggered by the early release of TNFa and IL-1. The therapeutic use of small molecular weight antagonists is more desirable than the use of large molecular weight glycoproteins or growth hormones to block the inflammation or shock process.
Materials and methods
The polyphenolic-sulfonated compounds found in [9, 10] . Evaluation of the induced edema was made by injecting 2% carrageenan in 0.9% saline into the plantar region of the foot. The opposite foot injected with 0.9% isotonic saline was used as a base line. Indomethacin (8 or 10 mg/kg), pentoxifylline (50 mg/kg) and phenylbutazone (50 mg/kg) were used as standards for comparison of activity. 
RESULTS

In Vivo Pharmacology Tests
The polyphenolic-sulfonate compounds proved to be potent anti-inflammatory agents and protected against endotoxin induced death in mice [ [19] . Thus, the polyphenolic sulfonates may play a similar role at these receptor binding sites, competing with the endogenous cytokines. Since TNF regulates IL-1, IL-6 and IL-8 as well as its own release, there is a possible cross-over in the effects of agents on the cytokine receptors. More than one receptor exists on cells for some of the cytokines, i.e. TNFtx and IL-1. What is most significant concerning these findings is that it may be possible to modulate cytokine effects on metabolism, proliferation, immunomodulation, etc., without using a large molecular weight protein that has deleterious side effects such as allergy and anaphaxisis. Numerous small molecular weight agents such as flavones, thalidomide, cyclosporin A, methotrexate, dexamethasone, or pentoxifylline, block TNFo or I1-1 synthesis or release from macrophages. Tenidap, which has structural features similar to the cyclic imides, appears to effect both I1-and TNFtx production and activation from human monocytes. All of the anti-inflammatory and antirheumatoid agents found to date require in vivo doses 3-50 mg/kg, yet the studies in tissue culture to block cytokine synthesis and release require IC50 values in the 0.2 to 0.5 mM range, i.e. IC50 value for pentamidine is 1 mM, IX 207-887 is 30-60 mM and hydrocortisone is 10 mM. The drug RP 54-745 decreases mRNA synthesis of both TNFct and IL-1 atter challenge with LPS. It is active in vivo at 25 mg/kg in mice but in vitro studies required 3 10 mM concentrations. Thus, the effect of polyphenolic sulfonate follows a similar pattem to other small molecular weight agents on cytokine modulation of the inflammation process. Because of these observations further investigation into their properties as potential therapeutic agents is needed.
